Inventor · disambiguated record
Natasja Brooijmans
Also filed as: BROOIJMANS NATASJA
13 granted patents·13 pending applications·262 citations·filing 2008–2024
92Inventor score
Top patents by PatentIndex Score
26 records- 0197US9340514B2Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2015·Granted May 17, 2016·43 cites·11 claims
- 0297US8802697B2Inhibitors of the fibroblast growth factor receptorBIFULCO JR NEIL·Filed 2013·Granted Aug 12, 2014·91 cites·9 claims
- 0396US9126951B2Inhibitors of the fibroblast growth factor receptorBIFULCO JR NEIL·Filed 2014·Granted Sep 8, 2015·47 cites·41 claims
- 0495US10017512B2Compounds and compositions useful for treating disorders related to NTRKBLUEPRINT MEDICINES CORP·Filed 2016·Granted Jul 10, 2018·29 cites·26 claims
- 0594US10202365B22-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitorsBLUEPRINT MEDICINES CORP·Filed 2016·Granted Feb 12, 2019·20 cites·15 claims
- 0693US11718602B2EGFR inhibitorsBLUEPRINT MEDICINES CORP·Filed 2022·Granted Aug 8, 2023·2 cites·8 claims
- 0793US10233186B2Inhibitors of activin receptor-like kinaseBLUEPRINT MEDICINES CORP·Filed 2017·Granted Mar 19, 2019·16 cites·56 claims
- 0892US10774070B22-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitorsBLUEPRINT MEDICINES CORP·Filed 2018·Granted Sep 15, 2020·6 cites·14 claims
- 0991US11970498B2CDK2 inhibitorsBLUEPRINT MEDICINES CORP·Filed 2023·Granted Apr 30, 2024·1 cites·26 claims
- 1090US11046697B2Compounds and compositions useful for treating disorders related to NTRKBLUEPRINT MEDICINES CORP·Filed 2018·Granted Jun 29, 2021·5 cites·20 claims
- 1189US11932648B2CDK2 inhibitorsBLUEPRINT MEDICINES CORP·Filed 2022·Granted Mar 19, 2024·1 cites·18 claims
- 1283US11634422B2Inhibitors of activin receptor-like kinaseBLUEPRINT MEDICINES CORP·Filed 2020·Granted Apr 25, 2023·1 cites·30 claims
- 1380US2025289801A1Egfr inhibitorsBLUEPRINT MEDICINES CORP·Filed 2024·Application pending·0 cites
- 1472US12172983B2EGFR inhibitorsBLUEPRINT MEDICINES CORP·Filed 2021·Granted Dec 24, 2024·0 cites·21 claims
- 1566US2019359682A1Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2018·Application pending·0 cites
- 1660US2024382483A1Heterocyclic egfr inhibitors for use in the treatment of cancerBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 1758US2024299387A1Heterocyclic egfr inhibitors for use in the treatment of cancerBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 1858US2017066812A1Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2016·Application pending·0 cites
- 1958US2024308981A1Heterocyclic egfr inhibitors for use in the treatment of cancerBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 2058US2024287040A1Substituted pyrimidinyl-pyrazoles as cdk2 inhibitorsBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 2153US2010015141A14-phenoxy-6-aryl-1h-pyrazolo[3,4-d]pyrimidine and n-aryl-6-aryl-1h-pyrazolo[3,4-d]pyrimidin-4-amine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesesWYETH CORP·Filed 2009·Application pending·0 cites
- 2251US2009181963A13H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESESWYETH CORP·Filed 2009·Application pending·0 cites
- 2350US2009227575A17H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESISWYETH CORP·Filed 2009·Application pending·0 cites
- 2448US2009298820A13-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesesWYETH CORP·Filed 2009·Application pending·0 cites
- 2548US2009311217A13-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesesWYETH CORP·Filed 2009·Application pending·0 cites
- 2647US2008233127A1Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitorsWYETH CORP·Filed 2008·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Natasja Brooijmans files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →